Daniel K Nishijima1, Michael C Monuteaux2, David Faraoni3, Susan M Goobie3, Lois Lee2, Joseph Galante4, James F Holmes1, Nathan Kuppermann5. 1. Department of Emergency Medicine, University of California Davis School of Medicine, Sacramento, California. 2. Division of Pediatric Emergency Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts. 3. Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts. 4. Division of Trauma and Emergency Surgery, Department of Surgery, University of California Davis School of Medicine, Sacramento, California. 5. Department of Emergency Medicine, University of California Davis School of Medicine, Sacramento, California; Department of Pediatrics, University of California Davis School of Medicine, Sacramento, California.
Abstract
BACKGROUND: The prevalence of tranexamic acid (TXA) use for trauma and other conditions in children is unknown. OBJECTIVES: The objective of this study was to describe the use of TXA in United States (US) children's hospitals for children in general, and specifically for trauma. METHODS: We conducted a secondary analysis of a large, administrative database of 36 US children's hospitals. We included children <18 years of age who received TXA (based on pharmacy charge codes) between 2009 and 2013. Patients were grouped into the following diagnostic categories: trauma, congenital heart surgery, scoliosis surgery, craniosynostosis/craniofacial surgery, and other, based on the International Classification of Diseases, Ninth Revision principal procedure and diagnostic codes. TXA administration and dosage, in-hospital clinical variables, and diagnostic and procedure codes were documented. RESULTS: A total of 35,478 pediatric encounters with a TXA charge were included in the study cohort. The proportions of children who received TXA were similar across the years 2009 to 2013. Only 110 encounters (0.31%) were for traumatic conditions. Congenital heart surgery accounted for more than one-half of the encounters (22,863; 64%). Overall, the median estimated weight-based dose of TXA was 22.4 mg/kg (interquartile range, 7.3-84.9 mg/kg). CONCLUSIONS: We identified a wide frequency of use and range of doses of TXA for several diagnostic conditions in children. The use of TXA among injured children, however, appears to be rare despite its common use and efficacy among injured adults. Additional work is needed to identify appropriate indications for TXA and provide dosage guidelines among children with a variety of conditions, including trauma.
BACKGROUND: The prevalence of tranexamic acid (TXA) use for trauma and other conditions in children is unknown. OBJECTIVES: The objective of this study was to describe the use of TXA in United States (US) children's hospitals for children in general, and specifically for trauma. METHODS: We conducted a secondary analysis of a large, administrative database of 36 US children's hospitals. We included children <18 years of age who received TXA (based on pharmacy charge codes) between 2009 and 2013. Patients were grouped into the following diagnostic categories: trauma, congenital heart surgery, scoliosis surgery, craniosynostosis/craniofacial surgery, and other, based on the International Classification of Diseases, Ninth Revision principal procedure and diagnostic codes. TXA administration and dosage, in-hospital clinical variables, and diagnostic and procedure codes were documented. RESULTS: A total of 35,478 pediatric encounters with a TXA charge were included in the study cohort. The proportions of children who received TXA were similar across the years 2009 to 2013. Only 110 encounters (0.31%) were for traumatic conditions. Congenital heart surgery accounted for more than one-half of the encounters (22,863; 64%). Overall, the median estimated weight-based dose of TXA was 22.4 mg/kg (interquartile range, 7.3-84.9 mg/kg). CONCLUSIONS: We identified a wide frequency of use and range of doses of TXA for several diagnostic conditions in children. The use of TXA among injured children, however, appears to be rare despite its common use and efficacy among injured adults. Additional work is needed to identify appropriate indications for TXA and provide dosage guidelines among children with a variety of conditions, including trauma.
Authors: David Faraoni; Ariane Willems; Christian Melot; Stefan De Hert; Philippe Van der Linden Journal: Eur J Cardiothorac Surg Date: 2012-04-24 Impact factor: 4.191
Authors: Daniel D Bohl; Glenn S Russo; Bryce A Basques; Nicholas S Golinvaux; Michael C Fu; William D Long; Jonathan N Grauer Journal: J Bone Joint Surg Am Date: 2014-12-03 Impact factor: 5.284
Authors: Matthew J Eckert; Thomas M Wertin; Stuart D Tyner; Daniel W Nelson; Seth Izenberg; Matthew J Martin Journal: J Trauma Acute Care Surg Date: 2014-12 Impact factor: 3.313
Authors: Anthony E Pusateri; Richard B Weiskopf; Vikhyat Bebarta; Frank Butler; Ramon F Cestero; Irshad H Chaudry; Virgil Deal; Warren C Dorlac; Robert T Gerhardt; Michael B Given; Dan R Hansen; W Keith Hoots; Harvey G Klein; Victor W Macdonald; Kenneth L Mattox; Rodney A Michael; Jon Mogford; Elizabeth A Montcalm-Smith; Debra M Niemeyer; W Keith Prusaczyk; Joseph F Rappold; Todd Rassmussen; Francisco Rentas; James Ross; Christopher Thompson; Leo D Tucker Journal: Shock Date: 2013-02 Impact factor: 3.454
Authors: Jeannie L Callum; Calvin H Yeh; Andrew Petrosoniak; Mark J McVey; Stephanie Cope; Troy Thompson; Victoria Chin; Keyvan Karkouti; Avery B Nathens; Kimmo Murto; Suzanne Beno; Jacob Pendergrast; Andrew McDonald; Russell MacDonald; Neill K J Adhikari; Asim Alam; Donald Arnold; Lee Barratt; Andrew Beckett; Sue Brenneman; Hina Razzaq Chaudhry; Allison Collins; Margaret Harvey; Jacinthe Lampron; Clarita Margarido; Amanda McFarlan; Barto Nascimento; Wendy Owens; Menaka Pai; Sandro Rizoli; Theodora Ruijs; Robert Skeate; Teresa Skelton; Michelle Sholzberg; Kelly Syer; Jami-Lynn Viveiros; Josee Theriault; Alan Tinmouth; Rardi Van Heest; Susan White; Michelle Zeller; Katerina Pavenski Journal: CMAJ Open Date: 2019-09-03
Authors: Daniel K Nishijima; John M VanBuren; Seth W Linakis; Hilary A Hewes; Sage R Myers; Matthew Bobinski; Nam K Tran; Simona Ghetti; P David Adelson; Ian Roberts; James F Holmes; Walton O Schalick; J Michael Dean; T Charles Casper; Nathan Kuppermann Journal: Acad Emerg Med Date: 2022-03-10 Impact factor: 5.221
Authors: Edward Compton; Rachel Y Goldstein; Alexander Nazareth; Stephen J Shymon; Lydia Andras; Robert M Kay Journal: Medicine (Baltimore) Date: 2022-01-14 Impact factor: 1.817
Authors: Daniel K Nishijima; John VanBuren; Hilary A Hewes; Sage R Myers; Rachel M Stanley; P David Adelson; Sarah E Barnhard; Matthew Bobinski; Simona Ghetti; James F Holmes; Ian Roberts; Walton O Schalick; Nam K Tran; Leah S Tzimenatos; J Michael Dean; Nathan Kuppermann Journal: Trials Date: 2018-10-30 Impact factor: 2.279